Encysive Avoids Additional Trials For Thelin Resubmission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Encysive Pharmaceuticals has relied on existing data to address lingering FDA concerns regarding the pulmonary arterial hypertension drug Thelin, the company said May 25, following discussions with the agency.
You may also be interested in...
Encysive’s Thelin "Approvable" For PAH: FDA Requests Additional Clinicals
An FDA "approvable" letter for Encysive’s pulmonary arterial hypertension drug Thelin (sitaxsentan) requests "additional clinical trial work," according to the firm.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product